

CURRICULUM VITAE

NAME:

Jinsil Seong, M.D., Ph.D.

ADDRESS

Department of Radiation Oncology, Yonsei University Medical College, Yonsei University Health System 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752 Korea

EDUCATION

1977.3.1-1983.2.28; Yonsei University College of Medicine, Seoul

1983.2.28; M.D.

1987.3.2-1989.2.28; M.S.in Medicine, Yonsei University Graduate School, Seoul, Korea

1989.3.2-1993.8.20; PhD in Medicine, Yonsei University Graduate School, Seoul, Korea

PROFESSIONAL BACKGROUND AND EXPERIENCES

2017.8.16- ; Vice-president, Asian Association of Radiation Research

2017.1.1-12.31; President, Korean Society of Radiation Bioscience

2017.6.30- ; Council member, Korean Liver Cancer Association

2016.11.7-11; Expert participation in Programme of Action in Cancer Treatment, operated by International Atomic Energy Agency (PACT) mission in Brunei

2016.9.1- ; Board member, Asian Clinical Oncology Society

2016.7.1-2017.6.30; President, Korean Liver Cancer Association

2016.6.1- ; Co-Chair, Asia Liver Radiation Therapy Study Group

2016.6.1-2018.5.30; Executive board, Korean Cancer Association

2015.7.1- ; Executive Secretary, Asia-Pacific Primary Liver cancer Expert (APPLE) association

2015. 3.1-2017.2.28; Executive board, Women in Nuclear Global (WIN-global)

2014.1.1- 2016.12.31 ; Global task force on Radiotherapy for cancer control in UICC

2013.5.1-2014.4.30; Scientific committee chair of Global Academic Program 2014 (GAP2014)

(Annual International Oncology Conference among M.D. Anderson Cancer Center and its 30 sister institutions)

2013.10.1-11.30; Consultant in Applied Radiation Biology and Radiotherapy in International Atomic Energy Agency (IAEA), Vienna, Austria

2013.7.4-7.18; Expert participation in Programme of Action in Cancer Treatment, operated by International Atomic Energy Agency (PACT) mission in Vietnam

2013.1.1-2016.12.31; Principal investigator representing Yonsei Cancer Center in Radiation Therapy Oncology Group (RTOG)

2013.1.1-2015.7.1; Council Member, Asia-pacific primary liver cancer expert (APPLE) association

2012.3.27-3.31; Expert participation in Programme of Action in Cancer Treatment, operated by International Atomic Energy Agency(PACT) mission in Philippines

2012.1.1- ; Editorial Board of Liver Cancer

2012.1.1- ; Editorial Board of Journal of Radiation Oncology

2010.3.1-2012.2.28; Yonsei Liver Cancer Study Group, president

2010.1.1- ; Council member, Asian Clinical Oncology Society

2009.9.-2015. 10.: Board member, Korean Society for Therapeutic Radiology and Oncology

2009.3.1-2012.2.27; Director in clinical affairs, Yonsei Cancer Center

2009.1.1- ; Council member, Korean Association of Study of Liver

2008.6.1-2016.5.30: Board member, Korean Cancer Association

2005.3.1-2009.2.28; Chairperson, Dept. of Radiation Oncology, Yonsei University Medical College

2005.3.1- ; Consultant for Multinational Clinical Trial, in International Atomic Energy Agency (IAEA)

2005.6.1-2007.5.31; Board of Multidisciplinary Team, Korean Association of Clinical Oncology

2004.3.1- ; Professor in Dept. of Radiation Oncology, Yonsei University College of Medicine

2003.10.1-2005.2.28; Chairperson, Department of Radiation Oncology, Yongdong Severance Hospital, Yonsei University Medical College

2003.1.1- ; Reviewer of American Journal of Clinical Oncology, Clinical Cancer Research, International Journal of Radiation Biology, Journal of Hepatology

2002.1.1-2012.12.31; Editorial Board of International Journal of Radiation Oncology Biology & Physics (American Society for Therapeutic Radiology & Oncology)

1999.3.1-2003.2.28; Associate professor in Dept. of Radiation Oncology, Yonsei University College of Medicine

1995.8.28-1996.11.15: Visiting Scientist, Dept. of Experimental Radiation Oncology, M.D. Anderson Cancer Center, Houston Texas, USA

1994.31.-1998.2.28; Assistant professor in Dept. of Radiation Oncology, Yonsei University College of Medicine

1992.3.1-1994.2.28; Instructor in Dept. of Radiation Oncology, Yonsei University College of Medicine

1990.9.1-1992. 2.28; Visiting Scientist, in Department of Experimental radiotherapy, M.D. Anderson Cancer Center, Houston Texas, USA

1987.3.1-1990.2.28; Research Fellow in Department of Radiation Oncology, Yonsei University Hospital and Yonsei Cancer Center

1983.3.1-1987.2.28; Intern and Residency training, Department of Radiation Oncology,
Yonsei Cancer Center, Seoul, Korea

MEMBERSHIP in Professional Academic Society

2018-; Active member, National Academy of Medicine of Korea
2010-; Active member, Asia-Pacific Primary Liver Cancer Expert Meeting
2010-; Active member, Asian Clinical Oncology Society
2007-; Active member, International Liver Cancer Association
2006-; Active member, Asia-Pacific Association of Study of Liver
2005-; Active member, Korean Association of Clinical Oncology
2000-; Active member, Korean Association of Study of Liver
2000-; Active member, Korean Liver Cancer Study Group
1997-; Active member, European Society for Therapeutic Radiology and Oncology
1996-2000: Active member, Radiation Research Society
1992-; Active member, American Society for Therapeutic Radiology and Oncology
1988-; Active member, Korean Association for Radiation Protection
1984-; Active member, Korean Cancer Association
1984-; Active member, Korean Society for Therapeutic Radiology and Oncology
1983-; Active member, Korean Medical Association

AWARDS:

2017.10.13. HDK The best academic award, Korean Society of radiation oncology
2017.3.21; Cancer prevention award, Korean Ministry of Health and Welfare
2016.12.9; The best scholar award, Korean Association of Radiation Bioscience
2012.6.13; Distinguished Scientific Award, Korean Cancer Association
2011.7.2; Best presentation award-bronze, 2nd Asia Pacific Primary Liver Cancer Expert meeting
2010.11.8; Best doctor award, Yonsei University Health System
2006. 5. 27; Best poster award, 12th Annual Meeting of Korean Association of Study of Liver
2005.12.17; Distinguished Scientific Award, 4th Japanese Society of Hepatology International
Conference
2005. 5. 28; Best poster award, 11th Annual Meeting of Korean Association of Study of Liver
2004. 2.17.; Young Investigator Award, International Congress of Liver Disease 2004
2003. 6.27; GSK Research Award, Korean Association of Liver Disease
2002. 6.15; SK Research Award, Korean Cancer Association
2002. 5.12; Award for the Outstanding Professor, Yonsei University
1996.10.18; Abbott Research Award, Korean Society for Therapeutic Oncology and Radiology

1994. 3.15; Award for the Best Scholar, Korean Foundation of Science and Technology

PUBLICATIONS

Non-SCI-listed journal

1. Seong J, Oh WY, Suh CO, and Kim GE: Radiotherapy of non-small cell lung cancer. J Korean Soc Ther Radiol 1984;2:213-219.
2. Cho KH, Seong J, Suh CO, and Kim GE : Radiation therapy for loco-regional recurrence of adenocarcinoma of rectum. J Korean Soc Ther Radiol 1984;2:237-243.
3. Park KR, Oh WY, Seong J, Suh CO, Kim GE, and Kim BS: Solitary plasmacytoma of the head and neck. J Korean Soc Ther Radiol 1985;3:35-40.
4. Seong J, Kim SG, Suh CO, Kim GE, and Loh JJK: Carcinoma of the tonsillar region; Results of external irradiation. J Korean Soc Ther Radiol 1986;4:29-34.
5. Seong J, Loh JJK, Suh CO, Kim GE, Chung HJ, Choi IJ, and Kim BS: The treatment results of non-metastatic Wilm's tumor by multimodality approach. J Korean Cancer Soc 1988;20:59-66.
6. Loh JJK, Seong J, Suh CO, Roh JK, Kim BS, and Kim GE: Hyperthermia using 8 MHz RF capacitive type in the treatment of cancer. J Korean Med Soc 1988;31:1229-1239.
7. Loh JJK, Lee CG, Seong J, Kim SG, Park KR, Suh CO, and Kim GE: The role of radiotherapy in management of rectal cancer. J Korean Soc Ther Radiol 1988;6:235-246.
8. Suh CO, Loh JJK, Seong J, Roh JK, Kim BS, Park IS, and Choi HJ: Effect of radiofrequency hyperthermia on hepatocellular carcinoma; Preliminary report. J Korean Cancer Soc 1988;20:117-125.
9. Loh JJK, Seong J, Suh CO, Kim GE, Kim BS, Kim JW, and Park TK: Combined radiotherapy and hyperthermia for locally advanced cervical carcinoma. J Korean Cancer Soc 1988;20:172-179.
10. Kim JH, Kim SK, Lee WY, Kim KH, Park YJ, Chang J, Koh EH, Ahn CM, Oh NH, Sohn HY, Roh JK, Cho BK, Hong SR, Hong PH, Choi KO, Lee KK, Seong J, Suh CO, Kim GE, Loh JJK, Kim BS: Combined Cyclophosphamide, Adriamycin, Cisplatin (CAP) chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. J Korean Med Soc 1988;31:850-863.
11. Loh JJK, Seong J Suh CO, Kim GE, Chu SS, Park KR, Lee CG, Kim BS, Kim SG, and Seel DJ: Cooperative clinical studies of hyperthermia using a capacitive type heating device GHT-RF8. Yonsei Medical Journal 1989;30:72-80.
12. Seong J, Lee YG, Suh Co, Loh JJK, Yoo HS, Roh JK, Kim BS, Han KH, Lee SI, and Choi HJ: Combined hyperthermia and radiation therapy on primary hepatocellular carcinoma. J Korean Cancer Soc 1989;21:117-128.

13. Seong J, Suh CO, Kim GE, Kim BS, and Loh JJK: Recurrent Wilm's tumor following primary treatment. *J Korean Cancer Soc* 1989;21:424-430.
14. Seong J, Chu SS, Yang SW, and Loh JJK: Unusual arrangement of electrodes in capacitive heating device. *J Korean Soc Ther Radiol* 1989;7:313-320.
15. Seong J, Loh JJK, Suh CO, Kim GE, Han KH, Lee SI, Roh JK, Choi HJ, and Kim BS: Combined radiotherapy and hyperthermia for nonresectable hepatocellular carcinoma. *J Korean Soc Ther Radiol* 1989;7:247-258.
16. Seong J: Hyperthermia in cancer treatment. *J Korean Med Women's Soc* 1989;14:29-41.
17. Lee JY, Suh CO, Seong J, Kim GE, and Loh JJK: Radiotherapy of paraaortic node metastases in carcinoma of the uterine cervix. *J Korean Soc Ther Radiol* 1989;7:259-267.
18. Lee HS, Moon SR, Ahn KJ, Chung EJ, Seong J, Kim GE, Loh JJK: Heterogeneity of T2N0 glottic cancer. *J Korean Soc Ther Radiol* 1990;8:199-205.
19. Seong J, Loh JJK, Kim GE, Suh CO, Kim JW, and Park TK: Postoperative radiotherapy for stage IB carcinoma of the uterine cervix. *Yonsei Medical Journal* 1990;31:367-374.
20. Ahn KJ, Chung EJ, Lee HS, Moon SR, Seong J, Kim GE, Loh JJK: Nasopharyngeal carcinoma under the age 30. *J Korean Soc Ther Radiol* 1990;8:183-188.
21. Lee HS, Chu SS, Seong J, Suh CO, Kim GE, Loh JJK, Kim YS, Kim SH, Chung SS, Han EK, Kim TS: Interstitial hyperthermia using 8MHz RF capacitive heating. *J Korean Soc Ther Radiol* 1991;9:27-36.
22. Suh CO, Loh JJK, Shin HS, Lee HS, Moon SR, Seong J, Chu SS, Kim GE, Han EK, Park CI: Effect of local hyperthermia on canine liver. *J Korean Soc Ther Radiol* 1991;9:37-46.
23. Song MH, Chung EJ, Seong J: Granulocytic sarcoma: Results of radiotherapy. *J Korean Soc Ther Radiol* 1992;10:261-266.
24. Pyo HR, Seong J, Shin HS, Lee HS, Kim GE, Suh CO, Loh JJK, Kim WC: The role of postoperative adjuvant radiation therapy to primary site in rectal cancer patients with synchronous liver metastasis. *J Korean Soc Ther Radiol* 1993;11:103-108.
25. Oh YT, Seong J, Shin HS, Kim GE: Biochemical changes of liver function in patients with hepatocellular carcinoma following radiotherapy and hyperthermia. *J Korean Soc Ther Radiol* 1993;11:109-118.
26. Shin HS, Seong J, Oh WY, Kim GE: Role of radiotherapy in unresectable pancreatic carcinoma. *J Korean Soc Ther Radiol* 1993;11:119-127.
27. Seong J: Radiation induced G2 chromatid break and repair kinetics. *J Korean Soc Ther Radiol* 1993;11:193-204.
28. Seong J, Suh CO, Kim GE: Adaptive response to ionizing radiation induced by low doses of gamma-rays in human lymphoblastoid cell lines. *J Korean Soc Ther Radiol* 1994;12:1-8.
29. Seong J, Kim GE: Adaptive response to ionizing radiation radiation induced by low dose of gamma-rays in human hepatoma cell lines. *Yonsei Medical Journal* 1994;35:77-83.

30. Chung WK, Kim SG, Lee CG, Seong JS, Kim GE: Concurrent chemoradiotherapy results in patients with anal cancer. *J Korean Soc Ther Radiol* 1994;12:99-108.
31. Seong J, Lee HS, Han KH, Chon CY, Suh CO, Kim GE: Combined treatment of radiotherapy and hyperthermia for unresectable hepatocellular carcinoma. *Yonsei Med J* 1994;35:252-259.
32. Kim MW, Lee KH, Chung JB, Seong J, Lee HR, Choi JH, Chung HC, Kim WC, Kum KC, Roh JK, Kim BS: The effect of combined chemoradiotherapy with or without hyperthermia in locally advanced pancreatic cancer. *J Korean Cancer Soc* 1994; 26:561-566.
33. Han KJ, Song SY, Chung JB, Kang JK, Seong J: Successful management by a new self-expandable and removable metallic coil stent insertion in a case with malignant obstructive jaundice associated with CBD stones at below and above the stricture. *J Korean Soc Gastrointest Endosc* 1994;14:402-408.
34. Seong J, Sung SH, Lee JW, Shin HS, Park CI, Kwon OH: Assessment of cell proliferation in primary and recurrent colorectal cancers. *J Korean Cancer Soc* 1995;27:223-229.
35. Seong J, Lee JD, Hong SJ, Kim GE: Strontium-89 treatment for painful bone metastases. *J Korean Cancer Soc* 1995;27:797-803.
36. Seong J, Lee JW, Chung EJ, Kim YT, Kim JW, Kim NK, Hong SJ, Choi EC, Lee WS, Kwon OH, Kim GE: Cell kinetics studies of human epithelial cancers with Bromodeoxyuridine labeling. *J Korean Cancer Assoc* 1995;27: 783-789.
37. Kim WC, Seong J, Kim GE; Role of radiotherapy in unresectable rectal cancers. *J Korean Soc Ther Radiol* 1995;13:173-180.
38. Kim KC, Han KH, Seong J, Park HJ, Chung JP, Lee KS, Chon JY, Moon YM, Park IS; Bleomycin-induced chromosomal sensitivity in hepatocellular carcinoma patients. *J Korean Soc Gastrointestinal Dis* 1996;28:382-390.
39. Chung EJ, Suh CO, Seong J, Keum KC, Kim GE. Treatment result of ovarian dysgerminoma *J Korean Soc Ther Radiol Oncol* 1996;14:221-228.
40. Seong J, Hunter N, Milas L. Induction of apoptosis and expression of apoptosis-related gene products in response to radiation in murine tumors. *J Korean Soc Ther Radiol Oncol* 1997;15:187-195.
41. Park W, Seong J, Keum KC, Suh CO, Lee SW, Lim JH, Min JS, Roh JK, Kim JH, Chung HC, Lee KK, Kim GE. The role of adjuvant postoperative radiotherapy in curative resectable sigmoid colon carcinoma. *J Korean Soc Ther Radiol Oncol* 1997;15:339-347.
42. Lim JH, Park W, Seong J, Suh CO, Kim GE, Min JS, Chung HC, Roh JK, Kim BS, Kim JY. Comparison of postoperative adjuvant radiation therapy alone vs. chemoradiotherapy in adenocarcinoma of the rectum. *J Korean Soc Ther Radiol Oncol* 1998;16:35-41.
43. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO, Kim GE. Combined treatment of transarterial chemoembolization and local radiotherapy for unresectable hepatoma *J Korean Soc Ther Radiol Oncol* 1998;16: 159-165.

44. Seong J, Shin HC, Kim GE, Suh CO. The effect of TNF- α on antitumor activity of radiation J Korean Soc Ther Radiol Oncol 1998;16: 225-231.
45. Lee SW, Kim GE, Chung KS, Lee CG, Seong J, Suh CO. A comparative study of predicting radiation hepatitis in 2-D and 3-D conformal radiotherapy for hepatocellular carcinoma. J Korean Soc Ther Radiol Oncol 1998;6:455-467.
46. Yeo IH, Seong J, Chu SS, Kim GE, Suh CO, Sandra E. Burch, Chris K. Wang Underatanding the response characteristics of x-ray verification film. J Korean Soc Ther Radiol Oncol 1998;16:505-515.
47. Seong J, Kim SH, Lee WJ, Suh CO, Min JS. Heterogeneity of radiation induced apoptosis in murine system J Korean Soc Cancer 1998;30:1259-1268.
48. Seong J. Radiotherapy of gastric cancer In: Kim JB eds. Gastric cancer 1999;pp265-27.
49. Cho JH, Seong J, Keum KC, Kim GE, Suh CO, Roh JK, Chung HC, Min JS, Kim NK. The effect of preoperative concurrent chemoradiotherapy in locally advanced rectal cancer. J Korean Soc Ther Radiol Oncol 2000;18:293-299.
50. Shin HS, Seong J. The role of radiotherapy in locally advanced gall bladder cancer. J Korean Soc Ther Radiol Oncol 2000;18:283-292.
51. Seong J, Kim SH, Suh CO. Enhancement of antitumor effect by combined chemo- radiation in murine hepatocarcinoma. J Korean Soc Ther Radiol Oncol 2000;18:329-336.
52. Park HC, Seong J, Lim JH, Kim GE, Han KH, Chon CY, Moon YM, Lee DY, Lee JT, Suh CO. The effect of radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. J Korean Soc Cancer 2000;32:220-228.
53. Chung EJ, Kim GE, Seong J, Yang WI, Kim YT, Suh CO. Clinical significance of apoptosis and the expression of p53 in stage IIB uterine cervical carcinoma treated with radiotherapy. J Korean Soc Cancer 2000;32:638-646.
54. Keum KC, Lee SW, Shin HS, Kim GE, Seong J, Lee CG, Chu SS, Chang SK, Suh CO. The measurement of set-up error and GTV movement using Electronic portal imaging device (EPID) in hepatocellular carcinoma. J Korean Soc Ther Radiol Oncol 2000;18:107-113.
55. Keum KC, Seong J, Suh CO, Lee SW, Chung EJ, Shin HS, Lim GE. Prediction of radiation hepatitis using normal tissue complication probability in hepatocellular carcinoma. J Korean Soc Ther Radiol Oncol 2000;18:277-282.
56. Lee S, Seong J, Kim YB, Cho KW, Kim JH, Chang SK, Kwon SI, Chu SS, Suh CO. Feasibility of respiration-reduction device system in radiotherapy of hepatocellular carcinoma. J Korean Soc Ther Radiol Oncol 2001;19:319-326.
57. Park HC, Seong J, Han KH, Chon CY, Moon YM, Song JS, Suh CO. Dose-response relation in radiotherapy of hepatocellular carcinoma. J Korean Soc Ther Radiol Oncol 2001;19:118-126.

58. Cho JH, Lim JH, Seong J, Oyo HR, Keum WS, Suh CO, Hong SJ. Bladder conservation with combined treatment of chemoradiation in muscle-invading bladder cancer. *J Korean Soc Ther Radiol Oncol* 2001;19:359-368.
59. Park HC, Suh CO, Seong J, Cho JH, Lim JH, Park W, Song JS, Kim GE. The effect of ondansetron and metochlopramide in management of nausea and vomiting in radiotherapy on abdomen: a phase III prospective randomized trial. *J Korean Soc Ther Radiol Oncol* 2001;19:127-135.
60. Oh WY, Song MH, Seong J, Suh CO. Regulation of apoptosis and cell cycle in murine cerebral tissue. *J Korean Soc Ther Radiol Oncol*, 2001;19:146-152.
61. Keum WS, Seong J, Lee MJ, Park HC, Han KH, Chon CY, Moon YM. radiotherapy of bone metastasis from hepatocellular carcinoma. *J Korean Soc Liver* 2002;8:304-311.
62. Kim SH, Seong J, Seong JK. Role of Fas in radiation-induced apoptosis. *J Korean Soc Ther Radiol Oncol*. 2002;20:246-252.
63. Kim YB, Seong J, Song SY, Park SW, Suh CO. concurrent chemoradiotherapy in unresectable pancreatic cancer. *J Korean Soc Ther Radiol Oncol*. 2002;20:328-333.
64. Keum KC, Park HC, Seong J, Chang SK, Han KH, Chon CY, Moon YM, Kim GE, Suh CO. The preliminary result of 3-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. *J Korean Soc Ther Radiol Oncol*, 2002;20:123-129.
65. Kim JS, Han KH, Lee DY, Seong J, Yoon YH, Chung JY, Ahn SH, Chon CY, Moon YM. Concurrent chemoradiotherapy in advanced hepatocellular carcinoma with portal vein thrombosis. *J Korean Soc Liver*. 2002;8:71-79.
66. Oh YT, Kang HJ, Kim MW, Chon M, Kang SH, Suh CO, Chu SS, Seong J, Kim GE. Measurement of 3-dimensional dose distribution using polymer gel and magnetic resonance imaging.. *J Korean Soc Ther Radiol Oncol*, 2002;20:264-273.
67. Lee CG, Kim CB, Chung KY, Lee DY, Seong J, Kim GE, Suh CO. The role of postoperative radiotherapy in esophageal cancer. *J Korean Soc Ther Radiol Oncol*, 2002;20:316-322.
68. Kim JH, Kim DY, Kim YH, Kim CY, Seong J. A survey of radiotherapy principle for rectal cancer in Korean radiation oncologist for the development of pattern of care study. *J Korean Soc Ther Radiol Oncol*, 2003;21:44-53.
69. Development of a device to analyze set-up error in radiotherapy. *J Korean Soc Ther Radiol Oncol*, 2003;21:100-106 .
70. Kim SH, Seong J, Suh CO. Role of Fas/Fas ligand in radiation-induced apoptosis. *J Korean Soc Ther Radiol Oncol*, 2003;21:222-226.
71. Kim SH, Seong J, Enhancement of radiosensitivity by MEK inhibitor in C3H/HeJ hepatocarcinoma. C3H/HeJ *J Korean Soc Ther Radiol Oncol*, 2003;21:207-215 .
72. Kim JH, Park JH, Kim DY, Kim WC, Seong J, Ahn YC, Yoo MR, Chon M, Hong SE. Determination of the optimal field size in postoperative radiotherapy of rectal cancer to develop pattern of care study. *J Korean Soc Ther Radiol Oncol*, 2003;21:183-191.

73. Seong J. Recent Development in Radiotherapy of Hepatocellular Carcinoma. Korean J Hepatol 2004;10:248-259.
74. Seong J. Proteomics of Protein Expression Profiling in Tissues with Different Radiosensitivity. J Korean Soc Ther Radiol Oncol, 2004;22(4):298-306.
75. Kim NK, Baik SH, Lee KY, Son SK, Cho CW, Min JS, Seong J, Chung HC, Rha SY. Preoperative Chemoradiation Followed by Total Mesorectal Excision for Locally Advanced Rectal Cancer: Oncologic Outcomes According to Pathologic T and N Stage. J Korean Surg Soc, 2005;68(3):218-223.
76. Seong J. High precision radiotherapy of hepatocellular carcinoma. J Korean Liver Cancer Study Group. 2005;5:1-6.
77. Kim DY, Han KH, Seong J, Ahn SH, Kim KS. Curative resection of advanced hepatocellular carcinoma after concurrent chemo-radiation therapy; a case report. J Korean Liver Cancer Study Group. 2005;5:22-26.
78. Shim SJ, Seong J. A case of intensity modulated radiotherapy in hepatocellular carcinoma. J Korean Liver Cancer Study Group. 2005;5:27-29.
79. Kim MW, Ahn SH, Paik YH, Lee KS, Chon CY, Moon YM, Seong J, Han KH. Two cases of acute hepatic decompensation after concurrent chemoradiotherapy in patients with advanced hepatocellular carcinoma. Jo Korean Liver Cancer Study Group. 2005;5:52-56.
80. Seong J, Lee IJ. Radiotherapy of biliary tract cancer, Korean J Pancreas and Biliary Tract. 2005;72-79.
81. Cho JH, Kim HC, Suh CO, Lee CG, Keum KC, Cho NH, Lee IJ, Seong J, Kim GE. Optimal radiotherapy schedule on uterine cervical cancer based on radiation dose and treatment technique. J Korean Soc Ther Radiol Oncol, 2005;23:143-156.
82. An JH, Seong J, Oh HJ, Kim WW, Han KH, Paik YH. Protein expression profiles in a rat cirrhotic model induced by thioacetamide. Korean J Hepatol 2006;12:93-102.
83. Chang SK, Seong J, Kim SH, Shin HS. Biological markers as predictors of radiosensitivity in syngeneic murine tumors. J Korean Soc Ther Radiol Oncol 2006;24:128-137.
84. Lee IJ, Seong J, Shim SJ, Han KH, Chon CY. Reappraisal of risk factors predicting liver complications from radiotherapy for hepatocellular carcinoma. Korean J Hepatol 2006;12:420-428.
85. Lee IJ, Seong J, Shim SJ, Jeong KK, Cho KW. Optimal radiation port arrangements for hepatic tumor using 3-dimensional conformal radiotherapy planning. J Korean Assoc Radiat Protect 2006;31:187-195.
86. Kang WS, Yoon KT, Park JY, Kim DY, Ahn SH, Chon CY, Kim KS, Seong J, Ha KH, A case report of hepatocellular carcinoma patient treated with curative surgical resection after successful concurrent chemoradiotherapy. J Korean Liver Cancer Study Assoc 2008;8:98-101.

87. You SW, Seong J, Koom WS. Perineal skin toxicity according to irradiation technique in radiotherapy of anal cancer. *J Korean Soc Ther Radiol Oncol* 2008;26:222-228.
88. You SW, Seong J, Lee IJ, Koom WS, Jeon BC. Treatment margin assessment using Megavoltage computed tomography of a Tomotherapy unit in the radiotherapy of a liver tumor. *J Korean Soc Ther Radiol Oncol* 2008;26:280-288.
89. Kim SY, You SW, Song T, Kim YN, Keum KC, Cho JH, Lee CG, Jinsil Seong. Superficial Dosimetry for Helical Tomotherapy. *J Korean Soc Ther Radiol Oncol* 2009;27:103-110.
90. Choi Y, Kim JW, Lee IJ, Han HJ, Baek J, Seong J. Helical tomotherapy for spine oligometastases from gastrointestinal malignancies. *Radiat Oncol J* 2011;29:219-27.
91. Cha J, Seong J, Keum KC, Lee CG, Koom WS. Comparison of elective inguinal node irradiation techniques in anal cancer. *Raidat Oncol J* 2011;29:236-42.
92. Lee IJ, Seong J, Bae JI, You SW, Rhee YM, Lee JH. Effect pf oral supplementation with branched chain amino acid (BCAA) during radiotherapy in patients with hepatocellular carcinoma; A double-blind randomized study. *Cancer Res Treat* 2011;43:24-31.
93. Min BS, Kim NK, Pyo JY, Kim HG, Seong J, Keum KC, Sohn SK, Cho CH. Clinical impact of tumor regression grade after preoperative chemoradiation for locally advanced rectal cancer; subset analyses in lymph node negative patients. *J Korean Soc Coloproctol* 2011;27:31-40.
94. Cha J, Seong J. Application of radiotherapeutic strategies in the BCLC-defined staged of hepatocellular carcinoma. *Liver Cancer* 2012;1:216-25.
95. Lee JS, Choi J, Choi C, Seong J. Role of radiotherapy for pancreatobiliary neuroendocrine tumors. *Radiat Oncol J* 2013;31:125-30.
96. Im JH, Seong J, Lee J, Kim YB, Lee IJ, Park JS, Yoon DS, Kim KS, Lee WJ. Postoperative radiotherapy dose correlates with locoregional control in patients with extra-hepatic bile duct cancer. *Radiat Oncol J*. 2014;32:7-13.
97. Lee DS, Seong J. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. *Liver Cancer*. 2014;3:18-30
98. Im CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. *Rad Oncol J* 2016;34:160-67.
99. Park HC, Yu JI, Cheng JC, Zeng ZC, Hong JH, Wang ML, Kim MS, Chi KH, Liang PC, Lee RC, Lau WY, Han KH, Chow PK, Seong J. Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. *Liver Cancer*. 2016 Jul;5(3):162-74.
100. Seo hee Choi, Joong Yeol Woo, Jinsil Seong. Selection of Proper Modality in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. *J Liver Cancer* 2017;17:45-53.
101. Seo hee Choi, Jinsil Seong. Strategic Application of Radiotherapy for Hepatocellular Carcinoma. *Clin Mol Hepatol* 2018 –E-pub

SCI(E)-listed Journals

1. Kim GE, Shin HS, Seong J, Loh JJK, Suh CO, Lee JT, Roh JK, Kim BS, Kim WH, Kim MW, Min JS. The role of radiation therapy in management of extrahepatic biliary metastasis from gastric carcinoma. *Int J Radiat Oncol Biol Phys* 1994;28:711-717.
2. Seong J, Suh CO, Kim GE. Adaptive response to ionizing radiation induced by low doses of gamma rays in human cell lines. *Int J Radiat Oncol Biol Phys* 1995;33(4):869-874.
3. Seong J, Milross CG, Hunter NR, Shin HC, Milas L. Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha. *Anticancer Drug* 1997;8:80-87.
4. Milross CG, Mason KA, Hunter NR, Terry NHA, Patel N, Harada S, Jibu T, Seong J, Milas L. Enhanced radioresponse of paclitaxel-sensitive and resistant tumors in vivo. *Eur J Cancer* 1997;33:1299-1308
5. Kim GE, Lim JH, Park W, Park HC, Chung EJ, Seong J, Suh CO, Lee YC, Park HJ.. Sensory and motor dysfunction assessed by anorectal manometry in uterine cervical cancer patients with irradiation induced late rectal complication. *Int J Radiat Oncol Biol Phys* 1998;41: 835-841.
6. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO, Kim GE. Combined transarterial chemoembolization and local radiotherapy for unresectable hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 1998;43: 393-397.
7. Akimoto T, Seong J, Hunter N, Buchmiller L, Mason K, Milas L. Assessment of increased radiocurability of murine carcinomas with low constitutive expression of p21WAF1/CIP1 protein. *Int J Radiat Oncol Biol Phys* 1999; 44:413-419
8. Chung EJ, Seong J, Yang WI, Park TK, Kim JW, Suh CO, Kim GE. Spontaneous apoptosis as a predictor of radiation response in patients with stage IIB squamous cell carcinoma of uterine cervix. *Acta Oncol* 1999;38:449.
9. Seong J, Park HC, Han KH, Lee JT, Lee DY, Chon CY, Moon YM, Suh CO. Local radiotherapy for unresectable hepatocellular carcinoma who failed with transarterial chemoembolization. *Int J Radiat Oncol Biol Phys* 2000;47:1331-1335.
10. Seong J, Kim SH, Chung EJ, Lee WJ, Suh CO. Early alteration in TGF-beta expression in irradiated rat liver. *Int J Radiat Oncol Biol Phys* 2000;46:639-643.
11. Seong J, Cho JH, Kim NK, Min JS, Suh CO. Preoperative chemoradiotherapy with oral doxifluridine plus low-dose leucovorin in unresectable primary rectal cancer. *Int J Radiat Oncol Biol Phys* 2000;50:435-439.
12. Seong J, Kim SH, Suh CO. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. *J Gastroenterol and Hepatol* 2001; 16:883-889.
13. Seong J, Kim SH, Pyo HR, Chung EJ, Suh CO. Effect of low-dose irradiation on induction of an apoptotic adaptive response in the murine system. *Radiat Env and Biophys* 2001; 40:335-339.

14. Kim GE, Lim JH, Park HC, Keum KC, Kim YB, Moon SR, Lee CG, Seong J, Suh CO. A feasibility study using three-dimensional conformal boost technique in locally advanced carcinoma of the nasopharynx. *Acta Oncol* 2001;40:582-587.
15. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2002; 54:150-155.
16. Seong J, Kim SH, Pyo HR, Chung EJ, Suh CO. Low-dose radiation-induced adaptive response in the murine system. *Ann NY Acad Sci* 2002; 973:255-257.
17. Seong J, Kim SH, Suh CO. Enhancement of radioresponse of murine tumors by ERK inhibitor. *Ann NY Acad Sci* 2002; 973:371-373.
18. Lee JD, Yang WI, Lee MG, Ryu YH, Park JH, Shin KH, Kim GE, Suh CO, Seong J. Effective local control of malignant melanoma by intratumoral injection of a beta-emitting radionuclide. *European J Nucl Med* 2002;29:221-230.
19. Han KH, Lee JT, Seong J. Treatment of nonresectable hepatocellular carcinoma. *J Gastroenterol Hepatol* 2002;17:424-427.
20. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular ca: a retrospective study of 158 patients. *Int J Radiat Oncol Biol Phys* 2003;55:329-336.
21. Seong J, Park HC, Han KH, Chon CY, Chu SS, Kim GE, Suh CO. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. *Hepatology research* 2003;27:30-35.
22. Seong J, Han KH, Park YN, Nam SH, Kim SH, Keum WS, Kim KS. Lethal hepatic injury by combined treatment of radiation plus chemotherapy in rats with thioacetamide-induced liver cirrhosis. *Int J Radiation Oncology Biology Physics* 2003;57:282-288.
23. Shin HS, Seong J, Kim WC, Lee HS, Moon SR, Lee IJ, Lee KK, Park KR, Suh CO, Kim GE. Combination of external beam irradiation and high dose rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile duct. *Int J Radiation Oncology Biology Physics* 2003;57:105-112.
24. Chae YS, Choi JS, Kim KS, Seong JS, Lee WJ, Kim BR. Preoperative chemoradiation and pancreaticoduodenectomy with portal vein resection for localized advanced pancreatic cancer. *Yonsei Med J*. 2003 Jun 30;44(3):551-6.
25. Seong J, Cho JH, Yang WI, Chung EJ, Kim NK. Apoptosis and proliferation in paired primary colorectal carcinomas and their liver metastasis. *Yonsei Med J* 2004;43:187-192.
26. Kim J, Seong J, Kim SH. Enhancement of tumor response by Farnesyl transferase inhibitor in C3H/HeJ Hepatocarcinoma. *Ann NY Acad Sci* 2004;1030:95-102.
27. An JH, Kim J, Seong J. Redox signaling by ionizing radiation in mouse liver. *Ann NY Acad Sci* 2004;1030:86-94.

28. Seong J, Park HC, Kim J, Kim UJ, Lee BH. Radiation-induced alteration of pain-related signals in an animal model with bone invasion from cancer. *Ann NY Acad Sci* 2004;1030:179-186.
29. Kim YB, Kim GE, Pyo HR, Cho NH, Keum KC, Lee CG, Seong J, Suh CO, Park TC. Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys* 2004;60:822-829.
30. Chung HW, Bang SM, Park SW, Chung JB, Kang JK, Kim JW, Seong J, Lee WJ, Song SY. A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2004;60:1494-1501.
31. Lee BW, Seong J, Kim UJ, Won R, Kim J. Behavioral Characteristics of a Mouse Model of Cancer Pain. *Yonsei Med J* 2005;46:252-259.
32. Park HC, Seong J, An JH, Kim J, Kim UJ, Lee BW. Alteration of cancer pain-related signals by radiation: proteomic analysis in an animal model with cancer bone invasion. *Int J Radiat Oncol Biol Phys* 2005;61:1523-1534.
33. Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. *Liver Int* 2005;25:1189-1196.
34. Seong J, Koom WS, Park HC. Radiotherapy for Painful Bone Metastases from Hepatocellular Carcinoma. *Liver Int* 2005;25:261-265.
35. Park EC, Yoon JB, Seong J, Choi KS, Kong ES, Kim YJ, Park YM, Park EM. Effect of ionizing radiation on rat tissue; proteomic and biochemical approach. *Preparative Biochemistry and Biotechnology* 2006;36:19-35.
36. Park JY, Park SW, Chung JB, Seong J, Kim KS, Lee WJ, Song SY. Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. *American J Clin Oncol* 2006;29:240-245.
37. An JH, Seong J. Proteomic analysis of apoptosis-regulating proteins in tissues with different radiosensitivity. *J Radiat Res* 2006;47:147-155.
38. Park Y, Sohn SK, Seong J, Paik SH, Lee KY, Kim NK, Cho CW. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. *J Surgical Oncol* 2006;93:145-150.
39. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC. Intermediate dose 5-fluorouracil-induced encephalopathy. *Jpn J Clin Oncol.* 2006 Jan;36(1):55-9
40. Kim NK, Baik SH, Seong JS, Kim H, Roh JK, Lee KY, Sohn SK, Cho CH. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. *Ann Surg.* 2006 Dec;244(6):1024-30

41. Seong J, Shim SJ, Lee IJ, Han KH, Chon CY, Ahn SH. Evaluation of the prognostic value of OKUDA, cancer of the liver Italian program, and Japan integrated staging system for hepatocellular carcinoma patients undergoing radiotherapy. *Int J Radiat Oncol Biol Phys* 2007;67:1037-1042.
42. Shim SJ, Seong J, Lee IJ, Han KH, Chon CY, Ahn SH. Radiation-induced hepatic toxicity after radiotherapy combined with chemotherapy for hepatocellular carcinoma. *Hepatol Res* 2007;10:149-153.
43. Kim W, Seong J, Oh HJ. Enhancement of tumor radioresponse by wortmannin in C3H/HeJ Hepatocarcinoma. *J Radiat Res* 2007;48:187-195.
44. Seong J, Oh HJ, Kim J, An JH, Kim W. Identification of proteins that regulate radiation-induced apoptosis in murine tumors with wild-type p53. *J Radiat Res* 2007;48:435-441.
45. Kim NK, Paik SH, Min BS, Pyo HR, Choi YJ, Kim H, Seong J, Keum KC, Rha SY, Shung HC. A comparative study of volumetric analysis, histopathology downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. *Int J Radiat Oncol Biol Phys* 2007;67:204-210.
46. Davidson SE, Trotti A, Atman OU, Seong J, Lau FN, Motta NW, Jeremic B. *Int J Radiat Oncol Biol Phys* 2007;67:1-4.
47. Kim YB, Shin KH, Seong J, JK Loh, GE Kim, SB Han, CO Suh. Clinical significance of margin status in postoperative radiotherapy for extremity and truncal soft-tissue sarcoma. *nt. J. Radiation Oncology Biol. Phys* 2008;70(1):139-144.
48. Cho JH, Kim GE, Rha KH, Ahn JB, Lee CG, Suh CO, Seong J, Keum KC, Lee SL, Lee YH. Hypofractionated High-Dose Intensity-Modulated Radiotherapy (60 Gy at 2.5 Gy per Fraction) for Recurrent Renal Cell Carcinoma: A Case of Report. *J Korean Med Sci* 2008;23:740-743.
49. KH Han, J Seong, JK Kim, SH Ahn, DY Lee, CY Chon. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. *Cancer* 2008;113(5):995-1003.
50. Song TS, Suh CO, Lee IJ, Jeong KK, Keum KC, Kee CG, Seong J, Cho JH. The Effect of Respiratory Motion on Forward Intensity Modulated Radiotherapy for Breast Cancer. *Technology in Cancer Research and Treatment* 2008;7(3):207-215.
51. Sunil Krishnan, Laura A. Dawson, Seong J, Yasuyuki Akine, Sam Beddar, Tina M. Briere, Christopher H. Crane, Françoise Mornex. Radiotherapy for Hepatocellular Carcinoma: An Overview. *Annals of Surgical Oncology* 2008;15:1015-1024.
52. Hong SP, Park JY, Jeong TJ, Bang S, Park SW, Chung JB, Park M-S, Seong J, Lee WJ, Song SY. Weekly full-dose gemcitabine and single dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. *British Journal of Cancer* 2008;98:881-887.

53. Kim YN, Lee CG, Jeong KK, Kim JY, Seong J. A Novel Method of 3-Dimensional Radiotherapy for Head-and-Neck Cancer Treatment. *Journal of Nuclear Science and Technology* 2008;Supplement 5 : 302-305.
54. Kim YN, Choi SH, Jeong KK, Kim JY, Lee CG, Seong J, Kim CH. A study on Optimization of Photoneutron Shielding in a Medical Accelerator Room by Using Monte Carlo Simulation. *Journal of Nuclear Science and Technology* 2008; Supplement 5:50-53.
55. Min BS, Choi YJ, Pho HR, Kim H, Seong J, Chung HC, Rha SY, Kim NK. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor response after preoperative chemoradiation in rectal cancer. *Arch Surg* 2008;143:1092-1097.
56. Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. *Int. J. Radiation Oncology Biol. Phys* 2009;73:1148-1154.
57. Seong J, Lee IJ, Shim SJ, Lim DH, Kim TH, Kim JH, Jang HS, Kim MS, Chie EK, Kim JH, Nam TK, Lee HS, Han CJ. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. *Liver Int* 2009; 29:147-152.
58. Kim HM, Bang SM, Park JY, Seong J, Song SY, Chung JB, Park SW. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. *Cancer Chemother Pharmacol* 2009;63:535-541.
59. Lee IJ, Seong J, Shim SJ, Han KH. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. *Int J Radiat Oncol Biol Phys* 2009;73:154-158.
60. Park MS, E Klotz, Kim MJ, Song SY, Park SW, Cha SW, Lim JS, Seong J, Chung JB, Kim KW. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. *Radiology* 2009;250:110-117.
61. Lee IJ, Seong J, Lee CG, Kim YB, Keum KC, Suh CO, Kim GE, Cho JH. Early clinical experience and outcome of helical tomotherapy for multiple metastatic lesions. *Int J Radiat Oncol Biol Phys* 2009;73:1527-1624.
62. Choi SB, Kim KS, Park YN, Choi JS, Lee WJ, Seong J, Han KH, Lee JT. The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. *J Korean Med Sci* 2009; 24:242-247.
63. Kim YB, Kim JH, Jeong KK, Seong J, Suh CO, Kim GE. Dosimetric comparisons of three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy in whole abdominopelvic radiotherapy for gynecologic malignancy. *Technol Cancer Res Treat* 2009;8:369-377.

64. Cho JH, Lee CG, Kang DR, Kim J, Lee S, Suh CO, Seong J, Suh YG, Lee I, Kim GE. Positional reproducibility and effects of a rectal balloon in prostate cancer radiotherapy. *J Korean Med Sci* 2009;24:894-903.
65. Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. *Yonsei Med J* 2009;50:601-612.
66. Park JK, Kim YW, Hur H, Kim NK, Min BS, Sohn SK, Choi YD, Kim YT, Ahn JB, Roh JK, Keum KC, Seong JS. Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection. *Langenbecks Arch Surg.* 2009 Jan;394(1):71-7
67. Kang JH, Kim YC, Kim H, Kim YW, Hur H, Kim JS, Min BS, Kim H , Lim JS, Seong J, Keum KC, Kim NK. Tumor volume changes assessed by three-dimensional magnetic resonance volumetry in rectal cancer patients after preoperative chemoradiation: the impact of the volume reduction ratio on the prediction of pathologic complete response. *Int J Radiat Oncol Biol Phys* 2010;76:1018-1025.
68. Koom WS, Seong J, Han KH, Lee JT. Is local radiotherapy still valuable for patient s with multiple intrahepatic hepatocellular carcinomas? *Int. J. Radiation Oncology Biol. Phys* 2010;77:1433-1540.
69. Oh H, Seong J, Kim W, Park S, Koom WS, Cho NH, Song M. Recombinant human epidermal growth factor protects radiation-induced intestine injury in murine system. *J Radiat Res* 2010;51:535-541.
70. Kim JW, Kim YB, Kim NK, Min BS, Shin SJ, Ahn JB, Koom WS, Seong J, Keum KC. The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis; a retrospective study. *Radiat Oncol* 2010; 5:75.
71. Chung SI, Seong J, Park YN, Kim W Kim, H Oh, KH Han. Identification of proteins indicating radiation-induced hepatic toxicity in cirrhotic rats. *J Radiat Res* 2010;51:643-650.
72. Chong YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Shin SK, Kim DY. Gastrointestinal complication after concurrent chemoradiotherapy in patients with hepatocellular carcinoma; Endoscopic findings with risk factors. *Int J Radiat Oncol Biol Phys* 2011;81:1343-1351.
73. Min BS, Kim NK, Pyo JY, Kim H, Seong J, Keum KC, Sohn SK, Cho CH. Clinical impact of tumor regression grade after preoperative chemoradiation for locally advanced rectal cancer ;subset analysis in lymph node negative patients. *J Korean Soc Coloproctol* 2011; 27:31-40.

74. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DT, et al. (18) F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. *Cancer* 2011; 117:4779-1487.
75. Lee IJ, Seong J, Bae JI, You SH, Rhee Y, Lee JH. Effect of oral supplementation with branched chain aminoacid (BCAA) during radiotherapy in patients with hepatocellular carcinoma; a double blind randomized study. *Cancer Res Treat* 2011;43:24-31.
76. Lee IJ, Seong J, Koom WS, Kim YB, Jeon BC, Kim JH, Han KH. Selection of the optimal radiotherapy technique for locally advanced hepatocellular carcinoma. *Jpn J Clin Oncol* 2011;41:882-889.
77. Lee IJ, Seong J. Radiosensitizers in hepatocellular carcinoma. *Semin Radiat Oncol* 2011; 21:303-311.
78. Kim W, Seong J, Oh HJ, Koom WS, Choi KJ, Yun CO. A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. *J Radiat Res* 2011;52:646-654.
79. Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. *Oncology* 2011;81 Suppl 1:123-133.
80. Park HC, Seong J, Tanaka M, Zeng, ZC, Lim HY, Guan S, Bae SH, Tak WY. Multidisciplinary management of nonresectable hepatocellular carcinoma. *Oncology* 2011; 81 Suppl1:134-140.
81. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T et al. Asian consensus workshop report expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. *Oncology* 2011;81 Suppl1:158-164.
82. Kim BK, Ahn SH, Seong JS, Park JY, Kim do Y, Kim JK, Lee do Y, Lee KH, Han KH. Early α -fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. *Liver Int.* 2011 Mar;31(3):369-76
83. Kim JW, Seong J, Yun M, Lee IJ, Yoon HI, Cho HJ, Han KH. Usefulness of positron emission tomography with Fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. *Int J Radiat Oncol Biol Phys* 2012; 82:1172-1178.
84. Lee MH, Kim SU, Kim DY, Shn SH, Choi EH, Lee KH, Lee DY, Seong J, Han KH, et al. Early on-treatment predictions of clinical outcomes using AFP and DCP responses in patients with advanced hepatocellular carcinoma. *J Gastroenterol Hepatol*, 2012;27:313-322.
85. Koom WS, Choi Y, Shim SJ, Cha J, Seong J, Kim NK, Keum KC. Reirradiation to the pelvis for recurrent rectal cancer. *J Surg Oncol* 2012;105:637-642.
86. Koom WS, Park SY, Kim W, Kim JS, Choi IK, Yun CO, Seong J. Combination of radiotherapy and adenovirus mediated p53 gene therapy for MDM-2overexpressing hepatocellular carcinoma. *J Radiat Res* 2012;53:202-210.

87. Chang JS, Wang ML, Koom WS, Yoon HI, Chung Y, Song SY, Seong J. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2012;83:1448-1454.
88. Yoon HI, Koom WS, Lee IJ, Jeong K, Chung Y, Kim JK, Lee KS, Han KH, Seong J. The significance of ICG R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. *Liver Int* 2012; 32:1165-1171.
89. Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, Kim EH, Seong J, Lee DY, Han KH. Applicability of BCLC stage for prognostic stratification in comparison with other staging system; single center experience from long term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. *Liver Int* 2012; 32:1120-1127.
90. Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. *Gut Liver* 2012; 6:139-148.
91. Park HJ, Kusnadi A, Lee EJ, Kim WW, Cho BC, Lee IJ, Seong J, Ha SJ. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. *Cell Immunol* 2012;278:76-83.
92. Cha J, Seong J. Application of radiotherapeutic strategies in the BCLC-defined stages of hepatocellular carcinoma, *Liver Cancer* 2012;1;216-25
93. Kang CM, Choi JY, Seong JS, Song SY, Lee WJ, Kim MJ, Chung JB. Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer. *Pancreas*. 2012 Apr;41(3):467-73
94. Park MS, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Chon CY, Seong J. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. *Cancer Chemother Pharmacol* 2013;71:165-173.
95. Lin SH, George TJ, Ben-Josef E, Bradley J, Choe KS, Edelman MJ, Guha C, Krishnan S, Lawrence TS, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman CN, Vikram B, Yoo S, Chung CH; on Behalf of the Participants on the Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. Workshop for Preclinical and Clinical Development of Radiosensitizers; National Cancer Institute. *J Natl Cancer Inst* 2013;105:686-693.
96. Cha H, Yoon HI, Lee IJ, Koom WS, Han KH, Seong J. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. *J Radiat Res* 2013; 54:1069-2077.
97. Chung MJ, Kim H, Jung YS, Shin SK, Hyung WJ, Noh SH, Seong J, Lee YC, Song SY. A pilot study for preoperative concurrent chemoradiotherapy with S-1 and cisplatin for locally advanced gastric cancer. *Hepatogastroenterology* 2013;60:382-386.

98. Kim YH, Yang HK, Kim TW, Lee JS, Seong J, Lee WY, Ahn YC, Lim HY, Won JH, Park KH, Cho KS. Report on the 10th International Conference of the Asian Clinical Oncology Society (ACOS 2012). *Gan To Kagaku Ryoho* 2013;40:424-429.
99. Chung MJ, Kim H, Jung YS, Shin SK, Hyung WJ, Noh SH, Seong J, Lee YC, Song SY. A pilot study for preoperative concurrent chemoradiotherapy with S-1 and cisplatin for locally advanced gastric cancer. *Hepatogastroenterology* 2013;60:382-386.
100. Cha J, Seong J, Lee IJ, Kim JW, Han KH. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. *Yonsei Med J* 2013;54: 1178-1185.
101. Choi Y, Kim JW, Cha H, Han KH, Seong J. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. *J Radiat Res* 2013; 55:113-120.
102. Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim do Y, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. *Onco Targets Ther* 2013;6:755-759.
103. Cho IR, Chung MJ, Bang SM, Park SW, Chung JB, Song SY, Seong J, Hwang HK, Kang CM, Lee WJ, Park JY. Gemcitabine based neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic cancer. *Pancreatology* 2013;13:539-543.
104. Park H, Kim SU, Park JY, Kim DY, Ahn SH, Chon CY, Han KH, Seong J. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. *Liver Int* 2014;34:313-321.
105. Yi SW, Kang DR, Kim KS, Park MS, Seong J, Park JY, Bang SM, Song SY, Chung JB, Park SW. Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. *Cancer Chemother Pharmacol* 2014;73:191-198.
106. Ju HL, Ahn SH, Kim do Y, Baek S, Chung SI, Seong J, Han KH, Ro SW. Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging. *PLoS One* 2013;8:e59869.
107. Choi Y, Kim J, Lee I, Seong J. Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies. *Liver Int* 2014: 34:462-68
108. Choi Y, Kim JW, Cha HJ, Han KH, Seong J. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. *J Rad Res* 2014;55:113-120.
109. Lee KJ, Kim HM, Jung JW, Chung MJ, Park JY, Bang S, Park SW, Lee WJ, Seong JS, Song SY. Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer. *Gut Liver*. 2013 Jan;7(1):106-11
110. Choi SH, Chang JS, Jeong YH, Lee Y, Seong J. FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma. *Liver Int* 2014;34:1118-25.

111. Kim KH, Kim MS, Chang JS, Han KH, Kim DY, Seong J. Therapeutic benefit of radiotherapy in huge (≥ 10 cm) unresectable hepatocellular carcinoma. *Liver Int* 2014;34:784-94.
112. Jeong KY, Seong J. Neonatal capsaicin treatment in rats affects TRPV1-related noxious heat sensation and circadian body temperature rhythm. *J Neurolo Sci* 2014;34:58-63.
113. Lee DS, Seong J. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. *Liver Cancer* 2014;3:18-30.
114. Yoon HI, Lee IJ, Han KH, Seong J. Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2014;140:1595-605.
115. Lee HS, Choi GH, Choi JS, Kim KS, Han KH, Seong J, Ahn SH, Kim DY, Park JY, Kim SU, Kim BK. Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy. *Ann Surg Oncol* 2014;21:3646-53.
116. Hong TS, Bosch WR, Krishnan S, Kim TK, Mamon HJ, Shyn P, Ben-Josef E, Seong J, Haddock MG, Cheng JC, Feng MU, Stephans KL, Robergo D, Crane C, Dawson LA. Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus; radiation therapy oncology group consensus guidelines. *Int J Radiat Oncol Biol Phys* 2014;89:804-13.
117. Lee EJ, Park HJ, Lee IJ, Kim WW, Ha SJ, Suh YG, Seong J. Inhibition of IL-17A Suppresses Enhanced-Tumor Growth in Low Dose Pre-Irradiated Tumor Beds. *PLoS One*. 2014;9:e106423.
118. Kim HM, Lee KJ, Cha J, Chung MJ, Bang S, Seong J, Song SY, Park SW. A pilot study of S-1 based chemoradiotherapy in patients with biliary tract cancer. *Cancer Chemother Pharmacol*. 2014;74:861-5.
119. Suh YG, Kim do Y, Han KH, Seong J. Effective biliary drainage and proper treatment improves outcomes of hepatocellular carcinoma with obstructive jaundice. *Gut Liver*. 2014;8:526-35.
120. Yu JI, Yoon SM, Park HC, Kim JH, Kim TH, Park JW, Seong J, Lee IJ, Jang HS, Kay CS, Kim CY, Chie EK, Kim JH, Kim MS, Choi YM. Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma. *Cancer Res Treat*. 2014; 46:348-57
121. Chang JS, Choi SH, Lee Y, Kim KH, Park JY, Song SY, Cho A, Yun M, Lee JD, Seong J. Clinical usefulness of (18)f-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy. *Int J Radiat Oncol Biol Phys*. 2014; 90:126-33
122. Lee IJ, Kim JW, Han KH, Kim JK, Kim KS, Choi JS, Park YN, Seong J. Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. *Yonsei Med J*. 2014; 55:1489-97

123. Choi C, Koom WS, Kim TH, Yoon SM, Kim JH, Lee HS, Nam TK, Seong J. A Prospective Phase 2 Multicenter Study for the Efficacy of Radiation Therapy Following Incomplete Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. *Int J Radiat Oncol Biol Phys.* 2014; 90:51-60
124. Oh TG, Chung MJ, Bang S, Park SW, Chung JB, Song SY, Seong J, Kang CM, Lee WJ, Park JY Validation of group B borderline resectable pancreatic cancer: retrospective analysis. *Gut Liver.* 2014; 8:557-62
125. Yoon HI, Seong J. Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma. *Oncology* 2014; 87: Suppl 1;90-8
126. Han HJ, Kim MS, Cha J, Choi JS, Han KW, Seong J. Multimodality treatment with radiotherapy for huge hepatocellular carcinoma. *Oncology* 2014; 87: Suppl 1;82-9
127. Suh YG, Lee EJ, Cha H, Yang SH, Seong J. Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy. *Dig Dis* 2014;32:725-732
128. Kang H, Chang JS, Oh TG, Chung MJ, Park JY, Park SW, Seong J, Song SY, Chung JB, Bang SM. Full dose gemcitabine is a more effective chemotherapy as first line treatment in locally advanced pancreatic cancer. *Chemotherapy* 2014;60:191-99.
129. Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality management for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. *Liver Cancer* 2014;3:406-16.
130. Lim S, Lee S, Lim JY, Park JS, Seong JS, Chang WS, Han KH, Choi HJ. Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma. *J Neurooncol* 2014;120:199-207.
131. Choi C, Seong J. Predictive Factors of Palliative Radiotherapy Response and Survival in Patients with Spinal Metastases from Hepatocellular Carcinoma. *Gut Liver.* 2015; 1:94-102
132. Hsu C, Chen B, Chen C, Ho M, Cheng J, Kokudo N, Murakami T, Yeo W, Seong J, Jia J, Han K, Cheng A. Consensus development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). *Liver Cancer* 2015;4:96-105.
133. Jeong K, Lee E, Yang S, Seong J. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. *J Rad Res* 2015;56:37-45.
134. Jeong K, Lee E, Kim S, Yang S, YC Sung, Seong J. Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. *Int J Cancer* 2015;137:721-30.
135. Korean Liver Cancer Study Group, National Cancer Center, Korea. 2014 Korean Liver Cancer Study Group -, National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. *Gut Liver* 2015;9:267-317.

136. Korean Liver Cancer Study Group, National Cancer Center, Korea. 2014 Korean Liver Cancer Study Group -, National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. *Korean J Radiol* 2015;16:466-522.
137. Yoon HI, Song KJ, Lee IJ, Kim DY, Han KH, Seong J. Clinical benefit of hepatic arterial infusion concurrent chemoradiotherapy in locally advanced hepatocellular carcinoma: A propensity score matching analysis. *Cancer Res Treat* 2016 Jan;48(1):190-7
138. Hsu C, Chen BB, Chen CH, Ho MC, Cheng JC, Kokudo N, Murakami T, Yeo W, Seong J, Jia JD, Han KH, Cheng AL. Consensus development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2014). *Liver Cancer* 2015;4:96-105.
139. Lee SH, Kang CM, Kim H, Hwang HK, Song SY, Seong J, Kim MJ, Lee WJ. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles. *Medicine* 2015;94:e2168.
140. Lee IJ, Lee EJ, Park H, Kim W, Ha SJ, Shin YK, Seong J. Altered Biological Potential and Radioresponse of Murine Tumors in Different Microenvironments. *Cancer Res Treat.* 2016 Apr;48(2):727-37
141. Im JH, Seong J, Lee IJ, Park JS, Yoon DS, Kim KS, Lee WJ, Park KR Surgery Alone Versus Surgery Followed by Chemotherapy and Radiotherapy in Resected Extrahepatic Bile Duct Cancer: Treatment Outcome Analysis of 336 Patients. *Cancer Res Treat.* 2016 Apr;48(2):583-95
142. Lee EJ, Lee SJ, Kim JH, Kim KJ, Yang SH, Seong J. Radiation Inhibits Interleukin-12 Production via Inhibition of C-Rel through the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Signaling Pathway in Dendritic Cells. *PLoS One* 2016; 11:e0146463
143. Lee KJ, Yoon HI, Chung MJ, Park JY, Bang S, Park SW, Seong JS, Song SY. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. *Gut Liver* 2016;10:323-9.
144. Lee SH, Kang CM, Bang SM, Choi JY, Seong JS, Hwang HK, Choi SH, Lee WJ. The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement. *Medicine (Baltimore)* 2015;94:e1233.
145. Kim JW, Seong J, Park MS, Kim KS, Park YN, Han KH, Lee IJ. Radiological-pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery. *J Gastroenterol Hepatol* 2016;3:1619-27
146. Park HC, Yu JI, Cheng JC, Zeng ZC, Hong JH, Wang ML, Kim MS, Chi KH, Liang PC, Lee RC, Lau WY, Han KH, Chow PK, Seong J. Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. *Liver Cancer.* 2016 Jul;5(3):162-74.
147. Kim YS, Kim JW, Yoon WS, Kang MK, Lee IJ, Kim TH, Kim JH, Lee HS, Park HC, Jang HS, Kay CS, Yoon SM, Kim MS, Seong J. Interobserver variability in gross tumor volume

- delineation for hepatocellular carcinoma : Results of Korean Radiation Oncology Group 1207 study. *Strahlenther Onkol.* 2016;192:714-21
148. Yoon HI, Jung I, Han KH, Seong J. The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma. *Oncotarget.* 2016; 7:62715-25
149. Han DH, Joo DJ, Kim MS, Choi GH, Choi JS, Park YN, Seong J, Han KH, Kim SI. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. *Yonsei Med J.* 2016 Sep;57(5):1276-81
150. Yoon HI, Seong J. Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma. *Liver Cancer.* 2016 Apr;5(2):139-51
151. Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. *J Natl Cancer Inst.* 2016 Jul 4;108(9).
152. Kim HJ, Lee WJ, Kang CM, Hwang HK, Bang SM, Song SY, Seong J. Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. *PLoS One.* 2016 Jun 22;11(6):e0157196. eCollection 2016
153. Kim T, Cha HJ, Kim JW, Seong J, Lee IJ. High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma. *Oncotarget.* 2016; 7;53921-29.
154. Kim JW, Seong J, Lee IJ, Woo JY, Han KH. Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. *Oncotarget.* 2016;7:40756-66.
155. Jung J, Yoon SM, Park HC, Nam TK, Seong J, Chie EK, Kim TH, Kim MS, Kim CY, Jang HS, Kim JH. Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). *PLoS One.* 2016 Mar 29;11(3):e0152642. eCollection 2016.
156. Lee DS, Woo JY, Kim JW, Seong J. Re-Irradiation of Hepatocellular Carcinoma: Clinical Applicability of Deformable Image Registration. *Yonsei Med J.* 2016;57(1):41-9.
157. Lee KJ, Yi SW, Cha J, Seong J, Bang S, Song SY, Kim HM, Park SW. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. *Cancer Chemother Pharmacol.* 2016;78(4):841-6.
158. Jung J, Yoon SM, Park HC, Nam TK, Seong J, Chie EK, Kim TH, Kim MS, Kim CY, Jang HS, Kim JH. Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). *PLoS One.* 2016 Mar 29;11(3):e0152642.
159. Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, Kim JW, Nam TK, Kim K, Jang HS, Kim JH, Kim MS, Yoon WS, Jung I, Seong J. Radiotherapeutic strategies for hepatocellular

carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. *Liver Int.* 2017;37:90-100

160. Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-fetoprotein and ¹⁸F-fluoro-2-deoxyglucose positron emission tomography. *Liver Int.* 2017;37:592-99.
161. Cha H, Park HC, Yu JI, Kim TH, Nam TK, Yoon SM, Yoon WS, Kim JW, Kim MS, Jang HS, Choi Y, Kim JH, Kay CS, Jung I, Seong J. Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group study (KROG 14-07). *Cancer Res Treat.* 2017;49:61-69.
162. Cha H, Lee EJ, Seong J. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. *World J Gastroenterol.* 2017;23:2077-85.
163. Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. *Strahlenther Onkol.* 2017;193:620-629.
164. Chung SY, Chang JS, Lee BM, Kim KH, Lee KJ, Seong J. Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. *Radiother Oncol.* 2017;123:438-445.
165. Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. *Oncotarget.* 2017 8:41242-55.
166. Rim CH, Choi C, Choi J, Seong J. Establishment of a Disease-Specific Graded Prognostic Assessment for Hepatocellular Carcinoma Patients with Spinal Metastasis. *Gut Liver.* 2017;11:535-542.
167. Zhao-Chong Zeng Jinsil Seong Sang Min Yoon Jason Chia-Hsien Cheng Ka-On Lam Ann-Shing Lee et al. Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. *Liver Cancer* 2017;6:264-274.
168. In Rae Cho, Hye Won Lee, Ki Jun Song, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Jinsil Seong, Kwang Hyub Han, Jun Yong Park. Conditional survival estimate in patients with BLCL stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. *Oncotarget.* 2017. 8:79914-26.
169. Jeong Eun Song, Kyu Sik Jung, Do Young Kim, Kijun Song, Jong Yun Won, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. *Int J Radiat Oncol Biol Phys.* 2017 99:396-406.

170. Youngkyong Kim, Hee Chul Park, Sang Min Yoon, Tae Hyun Kim, Jieun Lee, Jinhyun Choi, Jeong Il Yu, Jin-Hong Park, Jong Hoon Kim, Joong-Won Park and Jinsil Seong. Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02). *Oncotarget* 2017.8:94450-94461.
171. Hyun Ju Kim, Sangjoon Park, Koyoing Jin Kim, Jinsil Seong. Clinical significance of soluble programmed cell death ligand-1 (sPD L-1) in hepatocellular carcinoma patients treated with radiotherapy. *Radiother Oncol* 129;130-135, 2018.
172. Byung Min Lee, Seung Yeun Chung, Jee Suk Chang, Kyong Joo Lee, and Jinsil Seong. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy. *Gut and Liver* 12;342-52.2-18.
173. Jae Uk Chong, Gi Hong Choi, Dai Hoon Han, Kyung Sik Kim, Jinsil Seong, Kwang-Hyub Han, and Jin Sub Choi. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. *Ann Surg Oncol E-pub.* 2018.
174. Na Lee Kim, Jinsil Seong. What role does locally ablative stereotactic body radiotherapy play versus radiofrequency ablation in localized hepatocellular carcinoma? *J Clin Oncol* 36:2560-61.
175. Sangjoon Park, Eun Jung Lee, Chai Hong Rim, and Jinsil Seong. Plasma cell-free DNA as a predictive marker after radiotherapy for hepatocellular carcinoma. *Yonsei Med J* 58;470-79, 2018.
176. Eun-Jung Lee, Seung-Hyun Yang, Kyoung-Jin Kim, Hyejung Cha, Seo Jin Lee, Ji-Hye Kim, Junkyu Song, Kyung-Hee Chun, Jinsil Seong. Inter-alpha inhibitor H4 as a potential biomarker predicting the treatment outcomes in patients with hepatocellular carcinoma. *Cancer Res Treat* 50:646-57, 2018.
177. Seo Hee Choi and Jinsil Seong. Stereotactic body radiotherapy: does it have a role in management of hepatocellular carcinoma? *Yonsei Med J* 59;912-22, 2018.
178. Seo Hee Choi, Seung Woo Park, Jinsil Seong. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. *Radiother Oncol e-pub.*2018
179. Seo Hee Choi and Jinsil Seong. Strategic application of radiotherapy for hepatocellular carcinoma. *Cli Mol Hepatol* 24;114-34, 2018.

Book Chapters

1. Seong J. Radiotherapy of gastric cancer. In: Kim JB editor. Gastric cancer. Seoul Korea: Medical Publishing; 1999, p.265-73.
2. Seong J. Radiotherapy for pancreatic cancer. In: Chung JB editor. Pancreatic cancer. Seoul Korea: Koonjs publishing; 2006, p.181-91.
3. Seong J. Radiotherapy of cholangiocarcinoma. In: Chung JB & Korean society of pancreatobiliary disease, editors. Cholangiocarcinoma. Seoul Korea: Koonja publishing; 2009
4. Alaa I, Dawson L, Imai R, Krishnan S, Ng I, Salminen E, Seong J, Stevens G (in the order of alphabet). Trends and practices in diagnosis and treatment of hepatocellular carcinoma. IAEA human health series No. 10, Vienna, International Atomic Energy Agency 2010
5. Yoon YB, Kim SH, Kim YH, Seong J. Pancreatic cancer. In: Park JG, Banj YJ, Ha SW editors. Oncology 2nd ed. Seoul Korea: Iljogak; 2012, p.313-38.
6. Lee IJ, Seong J. Use of branched chain amino acids during radiotherapy. In: Rajendram R, Preedy VR, Patel VB. Editors. Branched chain amino acids in clinical nutrition vol 2. New York, NY: Human Press; 2015, p.289-98.
7. Choi JH, Seong J. Radiation therapy. In: Sun-Whe Kim, Hiroki Yamaue Editors. Pancreatic cancer. Springer-Verlag Berlin Heidelberg 2017, p 421-436
8. Lee IJ, Seong J. Evaluation of effect of neoadjuvant therapy using positron emission tomography. In; Hiroki Yamaue, Sun-Whe Kim Editors. Innovation of diagnosis and treatment for pancreatic cancer. Springer-Verlag Berlin Heidelberg 2017, p 45-58
9. Choi JH, Seong J. Radiation therapy. In: Dong Ki Lee, Don Hang Lee, Seung Woo Park Editors. Pancreatology. Kun-Ja publishers 2018, p527-545

Patents

1. 2016.8.19. Patent No. 10-1651171. A novel liver cancer therapeutic complex using IL-12 expressing mesenchymal stem cell. Jinsil Seong

Invited Talks

1. 1999.11.17-19 Yokohama, Japan, International Symposium of Future Development on Radiation Oncology, Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma
2. 1999.4.11 Daegu, Korea, International Symposium for 2000-International Congress of Hyperthermic Oncology, Preoperative concurrent chemoradiotherapy for locally advanced rectal cancer

3. 2000.7.1 Seoul, Korea, Yonsei International Radiation Oncology Symposium, 3-D conformal therapy in hepatoma
4. 2000.8.26, Seoul, Korea, The 2nd Annual Symposium of Korean Liver Cancer Study Group
2002.11.16 International symposium 2002: Molecular targeting in chemoradiotherapy, Chemoradiotherapy in gastrointestinal cancers
5. 2002.6.20-21 Seoul, Korea, The 28th Annual Meeting of Korean Association, Biological basis of chemoradiotherapy in cancer treatment
6. 2002.10.31-11.2 The 54th Annual meeting of Korean Society of Surgery, A new approach of radiotherapy in cancer treatment
7. 2002.7.13 Seoul, Korea, The 5th Annual Symposium of Korean Liver Cancer Study Group, A role of radiotherapy in locally advanced and metastatic hepatocellular carcinoma
8. 2003.2.8 Seoul, Korea, The Annual Symposium of Korean Liver Cancer Study Group, A guideline in radiotherapy of hepatocellular carcinoma
9. 2003.6.7 Seoul, Korea, Yonsei Colorectal Cancer Research Meeting Symposium, Radiotherapy for liver metastasis from colorectal cancers
10. 2003.10.16 Philadelphia, USA, Radiation Oncology Seminar in University of Pennsylvania, Philadelphia, Role of radiotherapy in management of hepatic tumors: clinical results and translational research
11. 2003.11.16-19, Seoul, Korea, 6th International conference of Asian Clinical Oncology Society, Chemoradiotherapy in hepatocellular carcinoma
12. 2003.11.21-23 2003, Jeju, Korea, International conference of science and technology, Early report of randomized trial comparing transarterial chemoembolization (TACE) alone vs. TACE plus radiotherapy on hepatocellular carcinoma larger than 3cm
13. 2003.11.6, Daejeon, Korea, Annual meeting of Korean Association of Radiation Protection, Translational Research in Radiation Oncology
14. 2004. 3.19 Houston, U.S.A., M.D. Anderson cancer Center Radiation Oncology Seminar, Role of radiotherapy in management of hepatic tumors-from bench to the clinic again
15. 2004. 4.17, Seoul, Korea, Annual symposium of Korean Study Group of Pancreatico-biliary disease, Role of radiotherapy in gall bladder carcinoma
16. 2004. 6.12 Seoul, Korea, Yonsei International Hepatoma Symposium, Role of radiotherapy in locally advanced hepatocellular carcinoma
17. 2004.10.15 Seoul, Korea, Korean Liver Cancer Study Group Seminar, Innovative Radiotherapy in Hepatocellular Carcinoma
18. 2004. 10.22 Seoul, Korea, Annual Meeting of Korean Society of Radiology, Role of radiotherapy in locally advanced hepatocellular carcinoma

19. 2004.11.12 Seoul, Korea, Yonsei Cancer Center 35th Anniversary Memorial Symposium, Role of radiotherapy in locally advanced hepatocellular carcinoma
20. 2004. 11.18 Seoul, Korea, Annual Meeting of Korean Gastrointestinal Disease Society, Therapeutic challenges in extrahepatic metastasis of hepatocellular carcinoma; the effect of radiotherapy
21. 2004.12.03 Seoul, Korea, Annual meeting of Korean Society of radiation Bioscience, Radioproteomics of Animal Model in Molecular Targeting
22. 2005.06.09-10, Beijing, China, Annual Meeting of Chinese Society of Radiation Protection, Normal tissue toxicity in radiotherapy for cancers
23. 2005.10.12 Houston, U.S.A., MD Anderson Grand Round Seminar, Determination of optimal radiotherapy in management of locally advanced liver cancer
24. 2005.7.9 Seoul, Korea, International Symposium of Yonsei Liver cancer Special clinic, What is optimal indication in radiotherapy for hepatocellular carcinoma?
25. 2005.11.22 Seoul, Korea, Single Topic Symposium of Korean Pancreatico-biliary Disease Study Group, Radiotherapy of biliary cancers
26. 2006.03.04 Seoul, Korea, Annual Meeting of Korea-Japan Radiation Technologists, Recent development in radiotherapy of hepatocellular carcinoma
27. 2006.3.25 Hong Kong, China, The First Lui Hac Minh Symposium Advanced Radiation Technology for Liver Cancer, Molecular Markers for Hepatic Toxicity by Radiation
28. 2006.03.25 Hong Kong, China, The First Lui Hac Minh Symposium Advanced Radiation Technology for Liver Cancer, Determination of optimal Radiotherapy in Management of Locally Advanced Liver Cancer
29. 2006.04.14 Kwangju, Korea, Whasoon Hospital Symposium, Optimization of precision radiotherapy in hepatocellular carcinoma
30. 2006.05.19 Seoul, Korea, 2006 Yonsei International Radiation Oncology Symposium, Application of high precision RT in HCC
31. 2006.6.17 Seoul, Korea, Pancreatico-biliary Cancers Clinic Symposium, Optimum Treatment for Locally Advanced Pancreatic Cancer
32. 2006.10.12 Daejun, Korea, Annual Symposium of Cancer Research Institute of Chungnam National University
33. 2006.12.04-8 Bangkok, Thailand, International IAEA symposium, Colorectal cancer
34. 2006.12.04-8 Bangkok, Thailand, International IAEA symposium, Tomotherapy
35. 2007.01.13 Houston, U.S.A., Hepatocellular carcinoma; Eastern & Western experiences, Combination of radiotherapy with other therapies; Eastern experience
36. 2007.03.29 Kyoto, Japan, 17th Asian Pacific Association of Study of Liver Conference, Effect of oral supplementation with BCAA during radiotherapy in patients with liver tumor

37. 2007.04.13 Seoul, Korea, 2007 Yonsei International Radiation Oncology Symposium, Tomotherapy in upper abdominal tumors
38. 2007.05.11 Jeju, Korea, 2007 Annual Symposium of Korean Society of Radiation Oncology, Clinical application of tomotherapy
39. 2007.05.19 Seoul, Korea, The 3rd Severance-MD Anderson Cancer Center Joint Symposium, Use of murine tumor model in development of combined therapeutic strategy overcoming radioresistance
40. 2007.06.06 Houston, U.S.A., The Methodist Hospital/Baylor College of Medicine Radiation Oncology Seminar, Challenge and Hope in radiotherapy of hepatocellular carcinoma
41. 2007.06.07 Houston, U.S.A., 3rd annual UT MD Anderson Cancer Center Sister Institution Conference, Precision radiotherapy using helical tomotherapy
42. 2007.09.01 Seoul, Korea, International symposium on radiation physics and radiation oncology, Precision radiotherapy using helical tomotherapy
43. 2007.09.06 Seoul, Korea, 2007 KFDA International workshop, Tomotherapy in radiation oncology
44. 2007.09.13 Daegu, Korea, Monthly seminar in Daegu-Kyungbook branch of Korean Society of Radiation Oncology, Tomotherapy
45. 2007.10.20, Seoul, Korea, Korea-Japan Single topic Symposium, Role of radiotherapy for pancreatic cancer
46. 2007.11.08 Seoul, Korea, NCCN-Korea cancer guideline meeting; Colon cancer, NCCN-Korea cancer guideline in radiotherapy of Colon cancer
47. 2008.1.12 Kurume, Japan, the 1st Korea-Japan liver cancer conference, Radiotherapy of hepatocellular carcinoma; challenge and hope
48. 2008.01.25 Orlando, U.S.A., Gastrointestinal Cancers Symposium of American Society of Clinical Oncology, Chemoradiation Therapy for Liver Tumors; Asian Perspective
49. 2008.02.23 Hong Kong, China, Asian Pacific Tomotherapy Symposium, Clinical application of tomotherapy
50. 2008.3.14 Seoul, Korea, 2008 Symposium of Liver Cancer Center in National Cancer Center, Radiotherapy of liver cancer
51. 2008.3.18 Seoul, Korea, Kyunghee University Seminar, Radiotherapy of hepatocellular carcinoma using tomotherapy
52. 2008.03.23 Seoul, Korea, Annual Meeting of Asian Pacific Study of Liver Disease, Promise and pitfall in radiotherapy of liver cancer
53. 2008.05.16 Daegu, Korea, Annual meeting of Korean Association of Study of Liver, Tomotherapy of hepatocellular carcinoma

54. 2008.06.12 Seoul, Korea, Annual meeting of Korean Cancer Association, Role of radiotherapy in hepatocellular carcinoma
55. 2008.06.28 Seoul, Korea, Annual meeting of Korean Society of Liver Cancer Study, Radiation therapy for advanced HCC with portal vein thrombosis
56. 2008.10.17 Seoul, Korea, Cancer Forum, Issues and solutions in application of radiotherapy
57. 2008.10.23 Vienna, Austria, Consultants' Meeting on Development of Guidelines for the Palliative Management of Common Cancers Using Radiotherapy in Limited Resource Setting; Liver cancer, Liver Cancer in Asia
58. 2008.11.01 Nagoya, Japan, Japanese Society of Clinical Oncology, Challenge and Hope in Radiotherapy of pancreatic Cancer
59. 2008.12.07 Bali, Indonesia, Asia Pacific Association of Study of Liver-single topic symposium, Precision radiotherapy of hepatocellular carcinoma
60. 2008.12.09 Seoul, Korea, 6th International meeting of hepatocellular carcinoma, Eastern and Western Experience, Radiotherapy of HCC with portal vein thrombosis
61. 2008.12.27 Taipei, Taiwan, International symposium of radiotherapy, Radiotherapy of HCC using Tomotherapy
62. 2009.06.13 Seoul, Korea, The 4th Anniversary Symposium of Yonsei Liver Cancer Special Clinic, Challenge and hope in radiotherapy of hepatocellular carcinoma
63. 2009.07.11 Busan, Korea, 2009 annual symposium of Dong-Ah University Center for Gastrointestinal disease, Radiotherapy of HCC: challenge and hope
64. 2009.08.28-29 Taipei, Taiwan, World Congress on Gastrointestinal Cancer: Asian Perspectives, Radiotherapy of Hepatocellular Carcinoma-Challenge and Hope
65. 2009.09.10-12 Seoul, Korea, 2009 Seoul International Liver Symposium, Locoreginal therapy for hepatocellular carcinoma
66. 2009.10.08-09 Seoul, Korea, 5th Trilateral symposium, Hypofractionated Radiotherapy in Upper Abdominal Tumors
67. 2009.11.14 Seoul, Korea, 2009 annual meeting of Korean Society of Hepatopancreatobiliary Surgery, A new management guideline for hepatocellular carcinoma; radiotherapy of hepatocellular carcinoma
68. 2010.01.23 Kurume, Japan, the 3rd Korea Japan Liver Cancer Conference, Radiotherapy of Locally advanced HCC
69. 2010.03.28 Beijing, China, 20th Conference of the Asia Pacific Association of Study of Liver, The role of radiotherapy in liver cancer
70. 2010.04.09 Kwangju, Korea, Whasoon Hospital Symposium, Practical issues in tomotherapy of hepato-pancreatic tumors

71. 2010.05.02 New Delhi, India, National workshop on liver cancer 2010, Challenge and hope in radiotherapy of hepatocellular carcinoma
72. 2010.06.01 Seoul, Korea, 9th Asia Pacific Congress of Cardiovascular Interventional Radiology, External beam radiotherapy of hepatocellular carcinoma
73. 2010.07.03-4 Incheon, Korea, 1st Asia-Pacific Primary Liver Cancer Expert meeting, multidisciplinary approach using radiotherapy
74. 2010.08.26 Hong Kong, China, World congress of gastrointestinal cancers; Asian perspectives, multidisciplinary approach using radiotherapy in locally advanced HCC
75. 2010.09.25 Bangkok, Thailand, Annual Meeting of Thailand Radiation Oncology Society, Challenge and hope in radiotherapy of HCC
76. 2011.02.17 Wonju, Korea, Tomotherapy Symposium, Clinical Challenges in Application of Helical Tomotherapy for Gastrointestinal Cancers
77. 2011.02.18 Seoul, Korea, Annual Radiation Oncology Symposium; Recent issues in Radiation Oncology, Hurdles in radiotherapy of hepatocellular carcinoma and how to overcome
78. 2011.07.01-03 Osaka, Japan, The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting, Indication of radiotherapy of HCC based on BCLC treatment guideline and more
79. 2011.08.26 Seoul, World Congress on Gastrointestinal Cancer: Asian Perspectives, Radiotherapy techniques in Hepatocellular carcinoma
80. 2011.10.08 Seoul, Korea, The 19th Annual Symposium of Yonsei University Research Institute of Gastrointestinal Disease, Evolution of Radiotherapy technology in GI Cancers
81. 2011.11.17 Seoul, Korea, Annual Symposium of Korean Cancer Association, New radiation modality; Tomotherapy
82. 2011.12.01-03 Jeju, Korea, Single Topic Symposium of Asia Pacific Association of Study of Liver, Critical appraisal of radiation therapy technology
83. 2012.01.14, Kurume, Japan, 5th Korea-Japan liver cancer meeting, Radiotherapy of hepatocellular carcinoma; when and how.
84. 2012.01.19-21 Seoul, Korea, 2012 Consensus Conference in Korean Association of Clinical Oncology, The role of radiotherapy in hepatocellular carcinoma
85. 2012.02.22 Seoul, Korea, 4th Tomotherapy Symposium, Concurrent chemoradiotherapy for locally advanced pancreatic cancer; Opening a window for hope.
86. 2012.03.28 Chiangmai, Thailand, Chiangmai university International symposium, Tomotherapy in Yonsei University
87. 2012.03.30 Phukett, Thailand, International Symposium of Thailand Radiation Oncology Society, Tackling frustrating cancer with Tomotherapy

88. 2012.06.14, Seoul, Korea, The 10th International Conference of the Asian Clinical Oncology Society, Selection of radiotherapy technology in hepatocellular carcinoma
89. 2012.06.29 Malaka, Malaysia, GUT 2012, Innovative role of radiotherapy in treatment of hepatocellular carcinoma
90. 2012.07.6-8 Shanghai, China, 3rd Asia-Pacific Primary Liver Cancer Expert Meeting, Radiotherapy technologies for hepatocellular carcinoma
91. 2012.07.6-8 Shanghai, China, 3rd Asia-Pacific Primary Liver Cancer Expert Meeting, Radiotherapeutic strategy according to BCLC stages in hepatocellular carcinoma
92. 2012.08.17 Shanghai, China, World Congress on Gastrointestinal Cancers-Asian Perspectives, Radiotherapy technologies for hepatocellular carcinoma
93. 2012.11.7-9 Hong Kong, China, International Cancer Conference, Clinical benefit of tomotherapy in liver tumor
94. 2012.11.7-9 Hong Kong, China, International Cancer Conference, Tackling frustrating cancer with tomotherapy; concurrent chemo-Tomotherapy for locally advanced pancreatic cancer
95. 2012.11.30 Seoul, Korea, International Symposium of Korean Society of Radiation Bioscience society, Tumor microenvironment and radiotherapy
96. 2012.1.26 Jakarta, Indonesia, Liver-GI Fair. Radiotherapeutic strategy according to BCLC stages in hepatocellular carcinoma
97. 2012.1.27 Jakarta, Indonesia, Liver-GI Fair. External Beam Radiotherapy in hepatocellular carcinoma
98. 2012.2.2. San Paulo, Brazil. Primary Liver cancer Joint Meeting-Brazil and Korea. Multimodal approach combining radiation therapy beyond standard therapy in hepatocellular carcinoma.
99. 2013.4.20. Seoul, Korea. Asan medical Center Asan Liver Center 3rd Symposium. Role of radiotherapy according to BCLC staging in the management of hepatocellular carcinoma
100. 2013.5.31. Seoul, Korea. AERO Liver Round table meeting. Research direction and collaboration in radiotherapy of hepatocellular carcinoma
101. 2013. 7.5~7. Busan, Korea. 4th Asian Pacific Primary Liver cancer Expert (APPLE) Meeting. Innovative targeted radiotherapy for hepatocellular carcinoma
102. 2013.7.6. Osaka, Japan. Japan Society of Interventional Radiology and Gastroenterology,. Radiotherapeutic strategy according to BCLC staging.
103. 2013. 8.12. Calgary, Canada, Medical Grand Round, Calgary University Medical Center. Application of Radiotherapy in Liver Cancer.
104. 2013.9.11. New York, USA, Radiation Oncology Grand Round, Albert Einstein Medical Center, Where are we in applying radiotherapy in hepatocellular carcinoma?

105. 2013.11.8 International Atomic Energy Agency, Vienna, Austria. Radiotherapy for Liver Cancer; Better Use of Radiotherapy for Better Health Outcome.
106. 2014.1.3. Oxford university, oxford, UK, Department of Oncology Research Seminar. Modulation of tumor microenvironment in cancer radiotherapy.
107. 2014.3.26. the 11th World Congress of the International Hepato-Pancreato-Biliary Association. Seoul, Korea. External beam radiotherapy for hepatocellular carcinoma; Where are we now?
- 108.2014.5.2. Global Academic Programs 2014-International Congress of MD. Anderson and its sister institutions. Seoul, Korea. Multimodality management for locally advanced BCLC stage C hepatocellular carcinoma.
109. 2014. 5.28. Special Workshop in Women In Korea. Jeju, Korea. Lessons from Fukushima accident.
110. 2014.5.6-8. International Kyoto Liver Symposium. Kyoto, Japan. Radiotherapy for advanced but liver confined hepatocellular carcinoma.
111. 2014.5.6-8. International Kyoto Liver Symposium. Kyoto, Japan. Targeted radiotherapy for hepatocellular carcinoma.
112. 2014.6.14. Liver week 2014, Jeju Korea. Overview of technical advances in radiotherapy of hepatocellular carcinoma.
113. 2014.7.11-13. Asia Pacific Primary Liver cancer Expert meeting 2014. Taipei, Taiwan, Radiotherapy, will have a place in guideline?
114. 2014.7.11-13. Asia Pacific Primary Liver cancer Expert meeting 2014. Taipei, Taiwan, Summary report of consensus committee; Radiotherapy of hepatocellular carcinoma.
115. 2014.8.29-30. The Korea-Japan Pancreatobiliary Collaborative Multicenter Symposium, Seoul, Korea. How to maximize therapeutic ratio of chemoradiotherapy in pancreas carcinoma; radiation oncologist's perspectives.
116. 2014.10.4-5. Taiwan Digestive Disease Week2014, Kaohsiung, Taiwan. multimodality management for locally advanced BCLC stage-C hepatocellular carcinoma
117. 2014.10.10-11. Korean Congress of Radiology, KCR2014, Seoul, Korea. Radiotherapeutic strategies in management of hepatocellular carcinoma.
- 118.2014.10.21-23, WIN-global, Sydney, Australia. Technical advances in radiotherapy of cancer; an example of liver cancer.
- 119.2014.12.5, Korean Society of Radiobioscience, Seoul, Korea. Radiation induced alteration of tumor microenvironment.
- 120.2014.12.20-21, International pancreas cancer Conference, Wakayama, Japan. How to maximize therapeutic ratio of chemoradiotherapy in pancreas carcinoma; radiation oncologist's perspectives

- 121.2015.5.25-29, International Congress of Radiation Research, Kyoto, Japan. Serum IL-6 as a Prognosis Predictor in Patients Treated with Radiotherapy for Hepatocellular Carcinoma
- 122.2015.6.18-20. Liver Week 2015, Busan, Korea. Radiation Therapy in HCC: implications from Korean Multicenter Registry Study.
- 123.2015.7.3-5, Asia Pacific Primary Liver Cancer Expert Meeting 2015, Osaka, Japan. Current status of radiotherapy in hepatocellular carcinoma and how to maximize therapeutic response.
- 124.2015.8.24-28, WIN-Global 2015, Vienna, Austria. Unmet needs in cancer radiotherapy in low to middle income countries
125. 2015.8.24. Gastroenterology seminar, Vienna general Hospital, Vienna, Austria; Radiotherapy in hepatocellular carcinoma
- 126.2015.9.9-12, KCR2015, Seoul, Korea. Radiotherapeutic Strategies in Management of Hepatocellular Carcinoma
- 127.2015.10.2-3, SGI 2015, Seoul, Korea. Optimal Treatment of HCC with PV invasion; Role of external beam radiotherapy.
- 128.2015.11.20. Annual Fall Symposium of Korean Cancer Association 2015, Seoul, Korea. Inflammatory cytokines as biomarkers predicting and modifying therapeutic outcome of radiotherapy in locally advanced hepatocellular carcinoma.
129. 2016.1.30. Recent update in radiation oncology2015, Seoul, Korea. Radiotherapy for gastrointestinal cancers
130. 2016.2.19-20. Yonsei Liver Center International symposium. Seoul, Korea. Maximizing the outcome of radiotherapy in locally advanced hepatocellular carcinoma
131. 2016.4.8. Asian Clinical Oncology Congress 2016. Delhi, India. Non-operative strategies for HCC: TACE, TARE, RFA, RT.
132. 2016. 4.10. Asia Pacific Association of Study of Liver Single Topic Symposium. Busan, Korea. Recent progress in radiotherapy
133. 2016.5.21. Chinese Society of Clinical Oncology HCC summit. Shanghai, China. Liver-directed therapy combining hepatic arterial infusion chemotherapy and local radiotherapy for locally advanced HCC.
- 134.2016.6.17-18. Korean Cancer Association Annual Meeting, Seoul, Korea. Radiotherapeutic Strategies in Management of Hepatocellular Carcinoma
- 135.2016.7.8-10. Asia pacific primary liver cancer expert congress, Hong Kong, China. Stereotactic radiotherapy of hepatocellular carcinoma(state of the art lecture)
- 136.2016.10.15. Shanghai international forum of liver cancer with PVTT, Shanghai, China. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumor thrombosis
- 137.2016.10.18. Liver cancer topic academy, Seoul, Korea. SBRT in HCC; clinical outcome and potential as immunoradiotherapy

- 138.2016.12.2. Annual Meeting of Korean Society of Radiation Bioscience. Seoul, Korea. Cancer Radiotherapy in the era of immunooncology.
- 139.2016.12.9. Asian Liver radiation therapy special interest group meeting, Shanghai, China. How to initiate research collaboration by SIG.
- 140.2016.12.16-19. European Society of Medical Oncology, Asian Perspectives. New development in locoregional therapy in hepatocellular carcinoma
- 141.2017.2.18. Annual meeting of Asia Pacific Association of Study of Liver, Shanghai, China. Current and future of radiotherapy in the treatment of HCC
- 142.2017.5.20. Hong Kong International Cancer Forum, Hong Kong, China. Advances in SBRT of HCC
143. 2017.5.21. Hong Kong-Shenzhen international cancer forum, Shenzhen, China. SBRT of HCC.
- 144.2017.6.16-18. Asia Pacific Association of Study of Liver single topic conference, Ulanbataar, Mongolia. Recent progress in radiotherapy of HCC.
- 145.2017. 6.23. The 24th Asia Pacific Cancer Conference, Seoul, Korea. Cancer prevention and treatment in Korea
- 146.2017. 6.23-24. The liver week 2017. Incheon, Korea. Liver directed concurrent chemoradiotherapy in locally advanced HCC.
- 147.2017. 7.6-7. Annual Meeting of Japanese Liver Cancer Study Group. Significance of radiotherapy for liver cancer
- 148.2017. 7.14-16. Asia Pacific Primary Liver Cancer Expert meeting 2018, Singapore, Liver hypertrophy by radiotherapy, Consensus workshop-radiation.
- 149.2017.9.15-17. International Liver Cancer Association Annual meetingm Seoul, Korea, Innovation in radiotherapy on hepatocellular carcinoma.
- 150.2017.9.23-26. Asia Pacific Digestive Week Annual Meeting, Hong Kong. Role of radiotherapy for cholangiocarcinoma.
- 151.2017.11.3. Annual meeting of Korean Pathology Society, Seoul, Korea. Cancer radiotherapy in the era of immunooncology.
152. 2018.1.13.Yonsei Insitute of Gastroenterology Symposium. Seoul, Korea. Combination of radiotherapy and immune check point inhibitor; enhancing efficacy and beyond
153. 2018.1.18-20. ASCO Gastrointestinal cancers symposium, San Francisco, USA. Stereotactic Body Radiotherapy: What Role Does Focal Radiotherapy Play for Hepatocellular Carcinoma?
154. 2018.2.17. 5th GI and liver international meeting, Yangon, Myanmar. Role of radio-interventions in management of HCC.

155. 2018.2.20-22. Asian Clinical Oncology Society, Chiangmai, Thailand. Multidisciplinary approach for locally advanced pancreatic cancer; Can we improve treatment outcome by radiotherapy?
156. 2018.4.21. Korean Liver Cancer Association- Liver Cancer School. Chunchun Korea; Evolving Roles of Radiotherapy in HCC.
157. 2018.4.27-28. Annual Meeting of Philippines Radiation Oncology Society, Manila, Philippines.; SBRT for liver cancer
158. 2018.5.11. Asian Pacific Association for the Study of the Liver Single Topic Conference. HCC; Strategy in the new era. Yokohama, Japan; Does radiation therapy have a role in HCC with vascular invasion?
159. 2018.5.14-17. Global Academic Program 2018, Stockholm, Sweden; Stereotactic radiotherapy vs. RF ablation for hepatocellular Ca: Propensity Score Matching Analysis
160. 2018. 7.4-6. Annual Meeting of Asia Pacific Primary Liver cancer Expert (APPLE) Association, Seoul, Korea. Application of radiotherapy to maximize patients benefit(?)
161. 2018. 9.6-8. 3rd FARO Scientific Meeting, Bali, Indonesia. Overview of SABR in HCC management based on BCLC staging system.
162. 2018. 11.2-4. Beijing liver cancer international conference, Beijing, China. What role dose radiotherapy have for hepatocellular carcinoma
- 163.2018.11.23-25. European Society for Medical Oncology in Asia, Singapore. Role of external beam radiotherapy evidence and comparison with other local treatment